20 June 2013
Keywords: gsk, ofatumumab, impresses, cll, trial, uk-based, drug
Article | 25 February 2008
UK-based drug major GlaxoSmithKline says that data from a Phase I/II trial of its anti-CD20 monoclonal antibody, ofatumumab, has
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 February 2008
19 June 2013
© 2013 thepharmaletter.com